Covidien Announces the Integration of the Nellcor OxiMax SpO2 System into Philips Patient Monitors

Collaboration increases accessibility of trusted technologies
BOULDER, Colo.--(Business Wire)--
Covidien (NYSE: COV), a leading global supplier of healthcare products, today
announced the integration of its Nellcor OxiMax oximetry system into Philips
IntelliVue and M-Series patient monitors. Philips is a leading global provider
of patient monitoring solutions, and the collaboration between the companies is
expected to significantly increase, in all major geographies, hospitals` and
healthcare providers` access to the industry-leading capabilities offered by
both companies.

Customers will have the added flexibility of choosing the Nellcor OxiMax
technology in Philips IntelliVue and M-Series patient monitors for critical care
areas such as the Intensive Care, Emergency, Anesthesia and Neonatal Care
departments. This enables the IntelliVue and M-Series patient monitors to be
compatible with Covidien`s Nellcor OxiMax specialty sensors, including the
Max-Fast forehead sensor for patients with poor perfusion and the SoftCare
nonadhesive sensor line for patients with sensitive skin, including newborns. In
the intensive care unit and other high-acuity areas of the hospital, Max-Fast
and SoftCare sensors support effective, comfortable care for the most critical
patients.

"Hospitals and clinicians are under constant pressure to improve outcomes and
decrease costs. In turn, they are demanding expanded access to the technologies
and medical devices they trust," said Chris Lowery, General Manager and Vice
President, Patient Monitoring, Covidien. "Covidien`s partnership with Philips
gives hospitals access to advanced technology from two leading medical
monitoring companies. The successful completion of this collaboration with
Philips, a recognized industry leader in patient monitoring, is consistent with
Covidien`s mission to provide products that help clinicians deliver safe and
efficacious patient care, while simultaneously maximizing hospital efficiency."

"Many clinicians have expressed great interest in Nellcor OxiMax technology in
our IntelliVue patient monitors," said David Russell, Vice President and Chief
Marketing Officer, Informatics and Patient Monitoring, Philips Healthcare. "This
collaboration enhances our ability to provide customers in the USA, Europe and
many other markets with a choice of their preferred trusted pulse oximetry
technology. This partnership also underscores Philips` commitment to providing
clear, accurate information to support clinical decision-making across all areas
of the hospital."

About Covidien

Covidien is a leading global healthcare products company that creates innovative
medical solutions for better patient outcomes and delivers value through
clinical leadership and excellence. Covidien manufactures, distributes and
services a diverse range of industry-leading product lines in four segments:
Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical
Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000
employees worldwide in 59 countries, and its products are sold in over 140
countries. Please visit www.covidien.com to learn more about our business.

Forward-Looking Statements

Any statements contained in this communication that do not describe historical
facts, including statements regarding the integration of certain Covidien and
Philips products, may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on current expectations of future events. If underlying
assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from the companies` expectations and
projections. Risks and uncertainties include, among other things, general
industry and medical device market conditions; technological advances and
patents attained by competitors; challenges inherent in the research and
development and regulatory processes; challenges related to product marketing,
such as the unpredictability of market acceptance for new medical device
products; inconsistency of treatment results among patients; the potential for
product failures; potential difficulties in manufacturing new products; and
governmental laws and regulations affecting domestic and foreign operations.
Covidien expressly disclaims any intent or obligation to update these
forward-looking statements except as required to do so by law.Additional
information concerning these and other risk factors can be found in press
releases issued by Covidien, as well as Covidien`s public periodic filings with
the Securities and Exchange Commission.

Covidien
Sherri Hughes-Smith
Manager, Media and Public Relations
Respiratory and Monitoring Solutions
303-581-6849
sherri.hughes-smith@covidien.com
or
Colman Lannum, CFA
Vice President
Investor Relations
508-421-4343
cole.lannum@covidien.com
or
Bruce Farmer
Vice President
Public Relations
508-452-4372
bruce.farmer@covidien.com
or
Brian Nameth
Director
Investor Relations
508-421-4363
brian.nameth@covidien.com

Copyright Business Wire 2009